Validation of a dissolution method with HPLC analysis for lasofoxifene tartrate low dose tablets.
A dissolution method with high performance liquid chromatography (HPLC) analysis was validated for an immediate release low dose tablet formulation. The method was validated to meet requirements for a global regulatory filing and this validation included specificity, precision, linearity, accuracy and range. Validation of precision included an intermediate precision study using an experimental design in order to satisfy Japanese regulatory requirements. In addition, filter suitability, standard and sample solution stability and method robustness were demonstrated. A statistical design of experiments was used for the robustness evaluation of both the dissolution method and the HPLC analysis method. All results were acceptable and confirmed that the method is suitable for its intended use.
Space
J Sean
JS
Pfizer Global Research and Development, Analytical Research and Development Department, Groton, CT 06340, United States. sean.j.space@pfizer.com
Opio
Alex M
AM
Nickerson
Beverly
B
Jiang
Hong
H
Dumont
Monica
M
Berry
Mark
M
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D020847:Estrogen Receptor Modulators / Q000032:analysis* / Q000737:chemistry; D015394:Molecular Structure; D011759:Pyrrolidines / Q000032:analysis* / Q000737:chemistry; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012995:Solubility; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods*; D013764:Tetrahydronaphthalenes / Q000032:analysis* / Q000737:chemistry; D013997:Time Factors
D020847:Estrogen Receptor Modulators; D011759:Pyrrolidines; D013607:Tablets; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene